Log In
BCIQ
Print this Print this
 

Praxbind, idarucizumab (BI 655075)

Also known as: dabigatran antidote

  Manage Alerts
Collapse Summary General Information
Company Boehringer Ingelheim GmbH
DescriptionFab fragment against dabigatran
Molecular Target
Mechanism of ActionAntibody; Reverse anticoagulant
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentMarketed
Standard IndicationBleeding
Indication DetailsReverse anticoagulant activity of dabigatran
Regulatory Designation U.S. - Breakthrough Therapy (Reverse anticoagulant activity of dabigatran);
U.S. - Priority Review (Reverse anticoagulant activity of dabigatran)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today